India, June 24, 2026: Bengaluru-based SwishX, the world's first agentic AI platform purpose-built for pharmaceutical and medtech companies, has been selected for the Anthropic and AWS Agentic AI Accelerator 2026 an India-first initiative supporting early-stage startups building next-generation agentic AI applications.
The Anthropic and AWS Agentic AI Accelerator 2026 that brings together a highly selective cohort of 40, early-stage startups building next-generation agentic AI applications capable of autonomously executing complex workflows rather than simply generating responses, officially begins on June 26, 2026 in Bengaluru. This program provides participating startups with technical mentorship, engineering and product guidance, access to Anthropic's frontier AI models and AWS cloud infrastructure, cloud credits, and opportunities to collaborate closely with AI researchers, product leaders, enterprise customers, and experts from Anthropic and Amazon Web Services (AWS).
SwishX has been recognised for building agentic AI specifically for the pharmaceutical industry, one of the world's most complex and highly regulated sectors. While AI adoption is accelerating across sectors, most commercial operations in pharma continue to rely on fragmented software, spreadsheets, manual workflows, and delayed reporting, limiting the speed and quality of business decisions.
SwishX addresses this challenge by building AI agents that go beyond generating insights - they autonomously execute complex commercial workflows and enable faster, data-driven decision-making. Its platform helps pharmaceutical companies identify which public tenders they have the highest probability of winning, detect revenue leakages across distribution channels, analyse real-time retailer sales, measure the effectiveness of doctor engagement initiatives, and optimize field force execution. By automating these traditionally manual processes, SwishX enables companies to improve commercial efficiency and increase revenue outcomes by up to 30%.
What distinguishes SwishX is its deep understanding of pharmaceutical commercial operations, particularly in emerging markets where fragmented distribution networks, government procurement, and complex compliance requirements create challenges that generic AI solutions are not designed to solve. Rather than offering a horizontal AI platform, SwishX has developed specialised AI agents trained to address industry-specific commercial problems at scale.
As pharmaceutical companies worldwide accelerate AI adoption with industry estimates suggesting AI could unlock $60–110 billion in annual value, SwishX is helping translate that potential into measurable business outcomes. Its selection into the Anthropic and AWS Agentic AI Accelerator reflects the company's ability to build enterprise-grade agentic AI that solves high-value, real-world problems in a sector where automation has historically lagged behind manufacturing and R&D.
Participation in the accelerator will enable SwishX to further strengthen its AI capabilities by leveraging Anthropic's frontier AI models alongside AWS's secure and scalable cloud infrastructure. The program provides access to world-class technical mentorship, AI infrastructure, and product expertise, enabling SwishX to accelerate innovation across its agentic AI platform. This will help the company build more intelligent, autonomous AI systems that enable pharmaceutical organizations to streamline commercial operations, improve decision-making, and unlock greater productivity across global markets.
Dushyant Sapre, Co-founder and CEO, SwishX, said, "We started SwishX with the belief that life sciences is one of the biggest untapped opportunities for agentic AI. While many industries embraced digital transformation, pharma commercial operations remained heavily dependent on fragmented workflows and manual processes. Our mission is to build AI agents that go beyond assisting users to autonomously execute complex commercial tasks. Being selected for the Anthropic and AWS Agentic AI Accelerator validates both our vision and the technology we're building. As AI evolves from copilots to autonomous agents, life sciences stand to benefit immensely from intelligent systems that deliver accuracy, transparency, and regulatory awareness. This program gives us the opportunity to collaborate with leading AI experts as we continue building enterprise-grade agentic AI for healthcare."
SwishX's long-term vision is to help life sciences organizations transition from manual, reactive commercial processes to autonomous AI-powered operations, enabling pharmaceutical companies to improve.
SwishX is a Bengaluru-based Agentic AI startup building the world’s first agentic AI platform for pharmaceutical, medtech, and life sciences companies. Built as a system of action, it combines autonomous AI agents, proprietary datasets, and real-time market intelligence to help companies improve sales execution, marketing, channel engagement, and commercial workflows.
The platform includes four products: Tender IQ (Agentic AI Tender & RFP Automation), Contract IQ (Agentic AI Hospital Rate Contract Automation), Marketing IQ (Agentic AI HCP & Rep Engagement), and Channel IQ (Agentic AI Channel Engagement).
Starting with India, SwishX is expanding across Southeast Asia, the Middle East, Africa, and Latin America, with a long-term vision to build a vertically integrated AI platform spanning the entire life sciences value chain.